Novartis Pharmaceuticals Sinimod Tablets China Approved for Market!
-
Last Update: 2020-05-12
-
Source: Internet
-
Author: User
Search more information of high quality chemicals, good prices and reliable suppliers, visit
www.echemi.com
Recently, the State Drug Administration approved the launch of the First Class of Innovative Drug Sinimod tablets (Commodity Name: Universal Energy), declared by Novartis PharmaAG, through the priority review and approval process, for the treatment of adult recurrent multiple sclerosis, including clinically isolated syndrome, recurrent-remission disease sympathis0 and active secondary progressive diseaseSinimod is an amoethanol-1-phosphate (S1P) receptor regulator that selectively binds to high affinity in S1P receptor subtype 1 (S1P1) and subtype 5 (S1P5), preventing lymphocytes from escaping from the lymph nodes and reducing the number of peripheral blood lymphocytesThe market ingresss of this variety provides new treatment options for patients with recurrent multiple sclerosis, which can better meet the clinical needs of patientsSiponimod (Mayzent) was approved by the FDA for the treatment of adult recurrent multiple sclerosis, including active secondary progressive multiple sclerosis (SPMS), recurrent recurrent multiple sclerosis (RRMS), and clinical isolation syndrome (CIS), the first FDA-approved oral drug to treat SPMS.
This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only.
This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of
the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed
description of the concern or complaint, to
service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content
will be removed immediately.
